Display options
Cite
Berber I, Erkurt MA, Nizam I, et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015;8(9):16308-14
Berber, I., Erkurt, M. A., Nizam, I., Koroglu, M., Kaya, E., Kuku, I., & Bag, H. G. (2015). Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. International journal of clinical and experimental medicine, 8(9), 16308-14.
Berber, Ilhami, et al. "Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience." International journal of clinical and experimental medicine vol. 8,9 (2015): 16308-14.
Berber I, Erkurt MA, Nizam I, Koroglu M, Kaya E, Kuku I, Bag HG. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015 Sep 15;8(9):16308-14. eCollection 2015. PMID: 26629149; PMCID: PMC4659037.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Sep 15;8(9):16308-14. eCollection 2015.

Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience.

International journal of clinical and experimental medicine

Ilhami Berber, Mehmet Ali Erkurt, Ilknur Nizam, Mustafa Koroglu, Emin Kaya, Irfan Kuku, Harika Gozukara Bag

Affiliations

  1. Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
  2. Department of Biostatistics and Medical Informatics, Inonu University School of Medicine Malatya, Turkey.

PMID: 26629149 PMCID: PMC4659037

Abstract

High-dose chemotherapy (HDC) applied together with autologous stem cell transplantation (ASCT) is a commonly used treatment modality in patients with malignant lymphoma. At present, there is a limited number of studies which compare toxicity and efficacy of various high-dose regimens applied in the treatment of malignant lymphoma. For this reason, the aim of this study was to investigate the efficacy and toxicity of BuCyE (busulfan, cyclophosphamide and etoposide) and BEAM (carmustine, etoposide, cytarabine and melphalan) preparative regimens in the patients with malignant lymphoma scheduled for autologous stem cell transplantation. Between November, 2010 and April, 2015, 42 patients with relapsed or refractory malignant lymphoma who underwent autologous stem cell transplantation following BEAM (n=11) and BuCyE (n=31) preparative regimens were analyzed at Bone Marrow Transplantation Unit of TurgutOzal Medicine Center in Turkey. The groups were compared in terms of patient characteristics, hematopoietic engraftment time, toxicity profiles and survival. No significant differences were detected between the groups with regard to age, gender distribution, international prognostic index, ASCT indications, disease status at the time of ASCT and type of lymphoma (P>0.05). Median number of infused CD34+ cells/kg, neutrophil and platelet engraftment statuses of BuCyE and BEAM groups were found to be similar (P>0.05). More patients in BuCyE group developed mucositis and nausea, but this difference was not statistically significant (P>0.05). A similar statistically insignificant difference was seen in that infectious complications occurred more commonly in BEAM group (P>0.05). Overall survival and event-free survival rates were not significantly different between the groups (P>0.05). BuCyE is a conditioning regimen which can be effectively used as an alternative to BEAM in the patients with malignant lymphoma undergoing ASCT. Moreover, toxicity rates of both regimens are similar. In order to comprehend the effect of each HDC regimen, further evidence-based data obtained from the studies involving larger sample sizes are required.

Keywords: BEAM; BuCyE; autologous transplantation; lymphoma

References

  1. J Clin Oncol. 1999 Apr;17(4):1244 - PubMed
  2. Bone Marrow Transplant. 1997 Sep;20(6):451-8 - PubMed
  3. N Engl J Med. 2004 Mar 25;350(13):1287-95 - PubMed
  4. Bone Marrow Transplant. 2007 Mar;39(6):335-40 - PubMed
  5. Bone Marrow Transplant. 1998 Feb;21(4):383-9 - PubMed
  6. Ann Hematol. 2002 Feb;81(2):96-102 - PubMed
  7. Bone Marrow Transplant. 2007 Nov;40(10):919-24 - PubMed
  8. Biol Blood Marrow Transplant. 2006 Dec;12(12):1343-9 - PubMed
  9. Bone Marrow Transplant. 2001 Feb;27(4):405-12 - PubMed
  10. Leuk Res. 2011 Feb;35(2):183-7 - PubMed
  11. Bone Marrow Transplant. 2000 Jun;25(12):1243-8 - PubMed
  12. N Engl J Med. 1993 Sep 30;329(14):987-94 - PubMed
  13. Bone Marrow Transplant. 1998 Jun;21(12):1171-5 - PubMed
  14. Leuk Lymphoma. 2003 Jul;44(7):1151-8 - PubMed
  15. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):313-6 - PubMed
  16. Semin Oncol. 1993 Aug;20(4 Suppl 4):50-4; quiz 55 - PubMed

Publication Types